Negative Research Results–Mostly Concealed in Journals_SharonBegley, WSJ
"Why are scientists coy about publishing negative data?
"Why are scientists coy about publishing negative data?
FDA's slip-shod approval of defective, harmful drugs, accompanied by rubber stampped endorsements by compromised FDA advisory committees may be reaching a boiling point.
The ethics of this radical drug experiment is being challenged by Dr. Jerald Block, a forthright psychiatrist and experienced system's analyst. His critical appraisal, published in the Bioethics Forum, Hastings Center Report.
Legislation is needed to ensure that conflicts of interest rules in medicine are enforced. One method for reigning in the abuse is to prohibit government grant awards to any researcher who violates financial conflict of interest rules.
Off-label prescribing of drugs for unapproved uses puts consumers at high risk of harm–but it is the single most lucrative marketing strategy.
Today's news report circulated by the media about the negative findings of a much touted, but uncontrolled observational study of depression (STAR*D) promotes the business interests of SSRI antidepressant drug manufacturers.
An Orwellian nightmare is being implemented on infants even as the evidence demonstrates that the psychiatry's practice guidelines are corrupted by
industry.
Business Week reports: "From 1986 to 2003 the number of nonsurgical cardiac procedures, such as propping open arteries with wire-mesh stents, rose twelve fold, according to the American Heart Association.
Medical researchers who commit fraud and research misconduct are caught only when a person of conscience steps up to the plate and blows the whistle. There are no systemic, independent checks and balances to prevent research fraud or abuse of patients.
AHRP InfoMail Return to Home Page Return to InfoMail Media Coverage List MediaCoverage News Stories on Human ResearchProtection andCommentary by Vera Hassner Sharav April 10a, 2002 U.S. Bio-Tech Start-ups Conducting CheapPreliminary Studies in China FYI Harvard University is not the only one exploiting China’spoor population for medical experiments. Violations of…
Jeffrey Drazen editor NEJM Turns Activist on Drug Trials Thu, 26 May 2005 Journal editors, one by one are trying to retrieve the integrity of their publications, at last recognizing that the pharamaceutical industry is a corrupting factor in medical research and the information disseminated about medicine. Jeffrey Drazen who…
The Crawford Resignation Mystery Sat, 24 Sep 2005 Merrill Goozner of Center for Science in the Public Interest provides insight into what may lie behind the sudden resignation of FDA Commissioner, Lester Crawford. Goozner surggests, “One possible clue to the administration’s thinking comes from the appointment of Andrew von Eschenbach,…